Navigation Links
AMDL Inc.'s JJB Plant Receives Production Approval From Chinese State Food and Drug Administration (SFDA)
Date:5/8/2009

TUSTIN, Calif., May 8 /PRNewswire-FirstCall/ -- AMDL Inc. (NYSE Alternext US: ADL), a US-based pharmaceutical company with major operations in China, announced today its JJB wholly foreign-owned subsidiary located in Shangrao, Jiangxi Province, China has received approval from the Chinese State Food and Drug Administration (SFDA) to re-initiate product production on its small injectable manufacturing line which is specifically used to produce the Goodnak(R) anti-aging injectable product and other small volume parenteral solutions.

The SFDA requires all China-based companies engaged in the manufacture of pharmaceutical products to have "Good Manufacturing Practices" (GMP) certification. In Q108, JJB's GMP certification expired and the Company initiated $1.5 million in plant renovations to bring the facility and its operations into compliance with the SFDA. With today's announcement, JJB has reopened the Jiangxi-based plant and resumed operations for its small injectable manufacturing line.

According to Mr. Douglas MacLellan, Chairman and CEO of AMDL, "Based on the pending renewal of our GMP-certification for the JJB plant we anticipated a temporary cease in operations at JJB and planned accordingly by successfully amounting adequate product supply to meet distributor demand through SFDA approval. The manufacturing lines at this facility have resumed operations and we remain on track with our quarterly and fiscal year business and financial projections."

For additional information on AMDL, its FY09 financial forecast, portfolio of international health and beauty products, and 2009 business strategy, visit the Company's website at www.amdl.com or contact AMDL Investor Relations at kszarkowitz@amdl.com .

About AMDL:

Headquartered in Tustin, CA with operations in China, AMDL Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The Company employs over 500 people in the US and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

    AMDL Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    kszarkowitz@amdl.com
    (Tel :) 206.310.5323


'/>"/>
SOURCE AMDL Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Preclinical study suggests organ-transplant drug may aid in lupus fight
2. Study provides hope that some transplant patients could live free of antirejection drugs
3. Study provides hope that some transplant patients could live free of anti-rejection drugs
4. Advanced Age No Bar to Liver Transplant
5. Nanowire coating for bone implants, stents
6. Circulating fats kill transplanted pancreas cells, study shows
7. Latest DES Analysis Stresses Importance of Physicians Well-Trained in Implantation Technique and Patient Follow-Up
8. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
9. Implantable device designed to detect, stop seizures under study at MCG
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. Bone-growing nanomaterial could improve orthopaedic implants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
Breaking Medicine Technology: